BioCryst Pharmaceuticals (BCRX) : 4 brokerage houses believe that BioCryst Pharmaceuticals (BCRX) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on BioCryst Pharmaceuticals (BCRX). Zacks Investment Research suggests a Hold with a rank of 3. 1 analysts perceive the stock to be overvalued at the existing levels, hence their call is to Sell the stock.The median of all the 8 Wall Street Analysts endorse the stock as a Buy with a rating of 2.13.
BioCryst Pharmaceuticals (BCRX) : The highest short term price target forecast on BioCryst Pharmaceuticals (BCRX) is $10 and the lowest target price is $3. A total of 6 equity analysts are currently covering the company. The average price of all the analysts is $6.33 with a standard deviation of $2.88.
Also, Major Brokerage house, PiperJaffray upgrades its ratings on BioCryst Pharmaceuticals (NASDAQ:BCRX). According to the latest information available, the shares are now rated Overweight by the analysts at the agency. Previously, the analysts had a Neutral rating on the shares. The rating by the firm was issued on August 12, 2016.
BioCryst Pharmaceuticals (NASDAQ:BCRX): After opening at $4.24, the stock dipped to an intraday low of $4.2 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $4.57 and the buying power remained strong till the end. The stock closed at $4.51 for the day, a gain of 5.87% for the day session. The total traded volume was 890,512. The stocks close on the previous trading day was $4.26.
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.